Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Nivo-lution in Mesothelioma.

Literature DB >> 31315884

Nivo-lution in Mesothelioma.

Aaron S Mansfield¹, Marjorie G Zauderer².

Abstract

The MERIT study was a single-arm, phase II clinical trial of nivolumab for the second- or third-line treatment of patients with malignant pleural mesothelioma in Japan. MERIT confirmed that PD-1 inhibition has activity in mesothelioma and led to the regulatory approval of nivolumab for the treatment of mesothelioma in Japan.See related article by Okada et al., p. 5485. ©2019 American Association for Cancer Research.

Entities: Chemical Disease Gene Species

Mesh：

Substances：
Nivolumab

Year: 2019 PMID： 31315884 PMCID： PMC6744981 DOI： 10.1158/1078-0432.CCR-19-1836

Source DB: PubMed Journal: Clin Cancer Res ISSN： 1078-0432 Impact factor: 12.531

12 in total

1. Neoantigenic Potential of Complex Chromosomal Rearrangements in Mesothelioma.

Authors: Aaron S Mansfield; Tobias Peikert; James B Smadbeck; Julia B M Udell; Enrique Garcia-Rivera; Laura Elsbernd; Courtney L Erskine; Virginia P Van Keulen; Farhad Kosari; Stephen J Murphy; Hongzheng Ren; Vishnu V Serla; Janet L Schaefer Klein; Giannoula Karagouga; Faye R Harris; Carlos Sosa; Sarah H Johnson; Wendy Nevala; Svetomir N Markovic; Aaron O Bungum; Eric S Edell; Haidong Dong; John C Cheville; Marie Christine Aubry; Jin Jen; George Vasmatzis
Journal: J Thorac Oncol Date: 2018-10-10 Impact factor: 15.609

2. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.

Authors: Gérard Zalcman; Julien Mazieres; Jacques Margery; Laurent Greillier; Clarisse Audigier-Valette; Denis Moro-Sibilot; Olivier Molinier; Romain Corre; Isabelle Monnet; Valérie Gounant; Frédéric Rivière; Henri Janicot; Radj Gervais; Chrystèle Locher; Bernard Milleron; Quan Tran; Marie-Paule Lebitasy; Franck Morin; Christian Creveuil; Jean-Jacques Parienti; Arnaud Scherpereel
Journal: Lancet Date: 2015-12-21 Impact factor: 79.321

3. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.

Authors: Evan W Alley; Juanita Lopez; Armando Santoro; Anne Morosky; Sanatan Saraf; Bilal Piperdi; Emilie van Brummelen
Journal: Lancet Oncol Date: 2017-03-11 Impact factor: 41.316

4. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.

Authors: Michele Maio; Arnaud Scherpereel; Luana Calabrò; Joachim Aerts; Susana Cedres Perez; Alessandra Bearz; Kristiaan Nackaerts; Dean A Fennell; Dariusz Kowalski; Anne S Tsao; Paul Taylor; Federica Grosso; Scott J Antonia; Anna K Nowak; Maria Taboada; Martina Puglisi; Paul K Stockman; Hedy L Kindler
Journal: Lancet Oncol Date: 2017-07-17 Impact factor: 41.316

5. Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma.

Authors: Josine Quispel-Janssen; Vincent van der Noort; Jeltje F de Vries; Marion Zimmerman; Ferry Lalezari; Erik Thunnissen; Kim Monkhorst; Robert Schouten; Laurel Schunselaar; Maria Disselhorst; Houke Klomp; Koen Hartemink; Sjaak Burgers; Wieneke Buikhuisen; Paul Baas
Journal: J Thorac Oncol Date: 2018-06-14 Impact factor: 15.609

6. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.

Authors: Nicholas J Vogelzang; James J Rusthoven; James Symanowski; Claude Denham; E Kaukel; Pierre Ruffie; Ulrich Gatzemeier; Michael Boyer; Salih Emri; Christian Manegold; Clet Niyikiza; Paolo Paoletti
Journal: J Clin Oncol Date: 2003-07-15 Impact factor: 44.544

7. Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study.

Authors: Luana Calabrò; Aldo Morra; Diana Giannarelli; Giovanni Amato; Armida D'Incecco; Alessia Covre; Arthur Lewis; Marlon C Rebelatto; Riccardo Danielli; Maresa Altomonte; Anna Maria Di Giacomo; Michele Maio
Journal: Lancet Respir Med Date: 2018-05-15 Impact factor: 30.700

8. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.

Authors: Luana Calabrò; Aldo Morra; Ester Fonsatti; Ornella Cutaia; Giovanni Amato; Diana Giannarelli; Anna Maria Di Giacomo; Riccardo Danielli; Maresa Altomonte; Luciano Mutti; Michele Maio
Journal: Lancet Oncol Date: 2013-09-11 Impact factor: 41.316

9. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial.

Authors: Maria J Disselhorst; Josine Quispel-Janssen; Ferry Lalezari; Kim Monkhorst; Jeltje F de Vries; Vincent van der Noort; Emmy Harms; Sjaak Burgers; Paul Baas
Journal: Lancet Respir Med Date: 2019-01-16 Impact factor: 30.700

10. Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma.

Authors: Ping-Chih Hsu; Jinbai Miao; Yu-Cheng Wang; Wen-Qian Zhang; Yi-Lin Yang; Chih-Wei Wang; Cheng-Ta Yang; Zhen Huang; Joanna You; Zhidong Xu; David M Jablons; Liang You
Journal: J Cell Mol Med Date: 2018-03-24 Impact factor: 5.310

3 in total